Manhattan Research’s Cybercitizen Health® U.S. study highlights top patient groups using mobile phones for health in 2013, helps marketers understand multichannel opportunities for 50+ patient and caregiver audiences
October 24, 2013, New York, NY
– The number of Americans using mobile phones for health information or tools reached 95 million in 2013, Manhattan Research’s Cybercitizen Health® U.S. 2013 study has found – up 27 percent from 75 million a year ago. Smartphones have become, for many, an indispensable source of healthcare information – 38 percent of online smartphone users agree that the device is “essential” for finding health and medical info.
For pharma marketers, having mobile-optimized websites is key in light of the growth of mobile health. The Cybercitizen Health® U.S. 2013 study found that consumers access health information on mobile phones at home, not just on the go, and that while adoption of mobile health apps from pharma companies is so far low, they are strongly influential for those users.
The study also shows that mobile health adoption, activities and attitudes vary greatly among the patient audiences tracked, highlighting the need for marketers to understand mobile behavior by unique therapeutic segments.
Online patient audiences who are most likely to be mobile health users:
1. Cystic fibrosis patients
2. Growth hormone deficiency patients
3. Acne patients
4. ADD/ADHD patients
5. Hepatitis C patients
6. Migraine patients
7. Crohn's disease patients
8. Chronic kidney disease patients
9. Generalized anxiety disorder patients
10. Bipolar disorder patients
Among online adults ages 18+ in condition groups where n is at least 50
“Many pharma marketers still underestimate both the opportunity and complexity of the mobile channel,” said Monique Levy, Vice President of Research at Manhattan Research. “Many marketers will need to reset assumptions around when, where and how these devices are used for health. What’s clear is that patients are using these devices throughout the patient journey, for quick questions and deep research, and increasingly to actually manage their condition and care.”
Manhattan Research surveyed 8,605 U.S. adults online and on the phone in Q3 2013 for the Cybercitizen Health® U.S. digital health study and advisory service, which helps pharmaceutical brand marketers understand how more than 50 patient and caregiver audiences interact with online and offline channels to make health and treatment decisions throughout the care journey. The research focuses on key media and marketing topics, including mobile, social, video, websites, TV, search, and email, as well as user content needs and interests. The study also highlights which resources are most influential on care choices and how digital is driving behavior offline, such as requesting treatment from healthcare professionals.
Dowload our Pharma Patient Mobile Support Opportunity Index
Download our Pharma Patient Mobile Support Opportunity Index from our latest Cybercitizen Health® U.S. study to see how mobile opportunities vary by multiple key patient audiences. Download here
Which Patient Audiences are Covered in Cybercitizen Health® U.S.?
Cybercitizen Health® U.S. provides in-depth profiles covering how 50+ patient and caregiver audiences use digital channels for health and treatment learning, decision making and care management, including Cancer, Hepatitis C, Hypertension, Type 2 Diabetes, Multple Sclerosis, Allergies, Rheumatoid Arthritis, Asthma, Parents of children with ADD/ADHD, Heart Disease, and many more. Audience segments can include diagnosed patients, Rx takers, caregivers and information-seekers.
Visit here for more information
or email email@example.com
About Cybercitizen Health® U.S. 2013
Cybercitizen Health® U.S. is Manhattan Research’s annual market research study and syndicated advisory service designed to help companies understand how consumers find, use and share health information and services online and empower them to make smarter marketing decisions in a digital world. The study surveyed 8,605 U.S. adults online and on the phone in Q3 2013. For more information, please visit www.manhattanresearch.com/cch